Procalcitonin (PCT) was measured on a Cobas 8000 platform (Roche Diagnostics, Basel, Switzerland) and interleukin (IL)-6 was measured on a Cobas e801 platform (Roche Diagnostics). C-reactive protein (CRP) levels were measured on a Cobas c702 platform by using the Tina-quant C-Reactive Protein assay (Roche Diagnostics).
Cobas e801 platform
Manufactured by Roche
Sourced in Switzerland
The Cobas e801 platform is an automated immunoassay analyzer designed for clinical laboratory settings. It is capable of performing a variety of immunoassay tests, including those for hormones, drugs, proteins, and other analytes. The Cobas e801 platform is intended to provide laboratories with efficient and reliable testing capabilities.
Automatically generated - may contain errors
Lab products found in correlation
Tina quant c reactive protein assay, by Roche (2 mentions)
Cobas 8000 platform, by Roche (1 mentions)
Quantstudio 7 system, by Thermo Fisher Scientific (1 mentions)
Dimension vista 1500 platform, by Siemens (1 mentions)
Architect i2000sr platform, by Abbott (1 mentions)
Unicel dxi 800 access, by Beckman Coulter (1 mentions)
Anti sars cov 2 elisa igg assay, by EUROIMMUN (1 mentions)
7 protocols using cobas e801 platform
1
Biomarker Measurement Protocol
2
Automated Elecsys IL-6 and CRP Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The fully automated Elecsys system on a cobas e801 platform (Roche Diagnostics, Basel, Switzerland) was used to measure single levels of IL-6, as described previously.16 (link)
,17 (link) The Elecsys IL-6 immunoassay has been standardized against the National Institute for Biological Standards and Control first international standard 89/548. C-reactive protein (CRP) levels were measured on a cobas c702 platform by using the Tina-quant C-Reactive Protein assay (Roche Diagnostics, Switzerland).
,17 (link) The Elecsys IL-6 immunoassay has been standardized against the National Institute for Biological Standards and Control first international standard 89/548. C-reactive protein (CRP) levels were measured on a cobas c702 platform by using the Tina-quant C-Reactive Protein assay (Roche Diagnostics, Switzerland).
3
Blood Sample Collection and Storage
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
At both visits, patients donated blood specimens by venipuncture, performed by trained study nurses. Samples for the study biobank were temporarily stored at 4°C, centrifuged at 2000g for 10 min and then transferred into aliquots that were frozen and stored at −80°C at Akershus University Hospital. Serum samples that had not previously been thawed were used to measure NT‐proBNP, which was analyzed by the electrochemiluminescence immunoassay Elecsys on the Cobas e 801 platform (Roche Diagnostics). The coefficients of variations reported by the manufacturer were 2.5% at 127 ng/L and 1.3% at 1706 ng/L.
4
Biomarker Analysis in COVID-19 Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood samples were collected at admission and on target day 3 (day 2-5 accepted) during hospitalization and stored at -80 °C in a study-specific biobank pending analysis. Measurements of interleukin-6 (IL-6), procalcitonin, ferritin, cardiac troponin T (cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed by the Elecsys immunoassay on the Cobas e801 platform (Roche Diagnostics, Rotkreuz, Switzerland). C-reactive protein was measured as part of clinical routine. Five patients had missing biobank samples, and for these cTnT, NT-proBNP and ferritin were recorded from the clinical routine measurements, while IL-6 and procalcitonin are reported as missing. SARS-CoV-2 RNA in plasma (viremia) was detected by reverse transcription real-time polymerase chain reaction on a QuantStudio 7 system (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Details of the laboratory analysis have been reported previously.14
5
Glycemic Biomarkers in Clinical Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HbA1c in mmol/L was measured within 24 h of enrolment on the Tosoh G8 platform (Sysmex Corporation, Kobe, Japan). P-glucose in mmol/L was measured at admission while fasting p-glucose and p-insulin in pmol/L were measured between 7:30 a.m. and 8:30 a.m. on the day after study enrolment after an overnight fast from 7:30 p.m. P-glucose was measured on the Dimension Vista® 1500 platform (Siemens Healthineers, Erlangen, Germany) and p-insulin on the Cobas e801 platform (Roche Diagnostics, Basel, Switzerland). Samples of fasting p-glucose and p-insulin from patients who received insulin during the fasting period were considered invalid.
6
Liver Cancer Biomarker Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum AFP, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), and cancer antigen 199 (CA-199) were analyzed on the Cobas e801 platform (Roche, Rotkreuz, Switzerland) and UniCel DxI 800 Access (Beckman Coulter, Brea, California, USA); Protein induced by vitamin K absence or antagonist-II (PIVKA-II) was analyzed on the ARCHITECT i2000SR platform (Abbott Park, Illinois, USA); HBsAg and HBeAg were analyzed on the EasyCuta platform (PerkinElmer, Taicang, Suzhou, China) following the manufacturers’ instruction and laboratory standard operating procedures. Serum AFP level lower than 20 ng/mL was defined as AFP negative, while it was defined as AFP positive if the concentration was higher than 20 ng/mL.
7
Comparative Evaluation of SARS-CoV-2 Antibody Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Euroimmun Anti-SARS-CoV-2 ELISA IgG assay (Euroimmun, Luebeck, Germany) was performed on serum samples on a Thunderbolt ELISA robot (Gold standard diagnostics, CA, US) according to the manufacturer's instructions. This ELISA provides a semi-quantitative in vitro determination of human IgG against SARS-CoV-2. The microplate wells are precoated with recombinant S1 structural protein. The results are evaluated by calculation of a ratio of the extinction of samples over the extinction of the calibrator. The sensitivity and specificity of samples > 10 days of disease duration are 80% and 99% respectively, according to the manufacturer (manual, March 2020).
The anti-SARS-CoV-2 Ig electrochemiluminescence (ECLIA) test (Roche Diagnostics, Rotkreutz, Switzerland), performed on the Cobas e 801 platform, detects antibodies to the recombinant nucleocapsid protein of SARS-CoV-2. The results are evaluated semi-quantitatively by calculation of the chemiluminescence of samples over the extinction of the calibrator. The sensitivity and specificity of samples > 14 days of disease duration according to the manufacturer are 99.5 % and 99.8 % respectively (manual, May 2020).
The anti-SARS-CoV-2 Ig electrochemiluminescence (ECLIA) test (Roche Diagnostics, Rotkreutz, Switzerland), performed on the Cobas e 801 platform, detects antibodies to the recombinant nucleocapsid protein of SARS-CoV-2. The results are evaluated semi-quantitatively by calculation of the chemiluminescence of samples over the extinction of the calibrator. The sensitivity and specificity of samples > 14 days of disease duration according to the manufacturer are 99.5 % and 99.8 % respectively (manual, May 2020).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!